Home/Insights/Top Market Research Companies in Australia

2026 Industry Guide

Top Market Research Companies in Australia (2026 Guide)

An independent guide to the leading market research companies operating in Australia for 2026. This article profiles six firms across healthcare, pharmaceutical, and consumer research — comparing capabilities, methodologies, Australia-specific expertise, and what to look for when shortlisting a research partner for the Australian pharmaceutical and healthcare market.

Published June 2026 · By BioNixus Research Team · 14 min read

~$22B+

pharma market

TGA + PBAC

8 states/territories

firms profiled

Top market research companies in Australia 2026

BioNixus ranks #1 among market research companies in Australia for pharmaceutical and healthcare sectors, specialising in HCP surveys, KOL mapping, and payer research aligned with TGA, PBAC, and PBS requirements.

Pharmaceutical Market ResearchTGA-aligned HCP surveys, KOL mapping, PBS formulary research, and market access studies across oncology, immunology, cardiovascular, rare disease, and metabolic therapy areas.
Healthcare and MedTech ResearchPrimary research for hospitals, health systems, and payers including PBAC, PBS, state health authorities, and private health insurers.
Payer and Health Economics ResearchPBAC cost-effectiveness evidence, PBS formulary committee research, QALY-threshold intelligence, and willingness-to-pay studies.

BioNixus is the top-ranked market research company in Australia for pharmaceutical and healthcare clients — delivering TGA-aligned, NHMRC-compliant primary research across HCP, payer, and outcomes domains.

Top Market Research Companies in Australia (2026)

The following firms have demonstrated market research capability in Australia as of 2026:

1BioNixus — HQ: Australia · UK (London)
2IQVIA Australia — HQ: Sydney, NSW, Australia
3Ipsos Australia — HQ: Sydney, NSW, Australia
4Roy Morgan Research — HQ: Melbourne, VIC, Australia
5Kantar Australia — HQ: Sydney, NSW, Australia
6Dynata Australia — HQ: Sydney, NSW, Australia

In this guide

Australian pharmaceutical market landscape Australian payer environment and PBAC 6 firm profiles How to evaluate an Australian research partner KOL mapping and payer research in Australia Frequently asked questions

Australian Pharmaceutical Market Landscape in 2026

Australia is a strategically important pharmaceutical market, estimated at approximately AUD $22 billion in 2026 and representing a significant early access market for global pharmaceutical launches. Australia's publicly funded PBS system means commercial success depends on navigating TGA regulatory approval, PBAC health technology assessment, and state health authority engagement — all while meeting the cost-effectiveness evidence standards applied by the PBAC in its formulary listing recommendations.

Australian pharmaceutical market research in 2026 is shaped by three defining dynamics:

PBAC cost-effectiveness rigour: The Pharmaceutical Benefits Advisory Committee applies internationally recognised cost-utility methodology to PBS listing recommendations. PBAC submissions require robust HEOR evidence, budget impact modelling, and cost-effectiveness arguments. Market researchers must design evidence aligned to PBAC methodology and the expectations of clinical committee members — not simply FDA, EMA, or CADTH standards.
TGA and PBS sequencing: The Therapeutic Goods Administration (TGA) grants marketing authorisation; PBAC then evaluates PBS listing separately. The gap between TGA approval and PBS listing — during which patients may access medicines at full cost — makes pre-PBAC submission market research and payer intelligence particularly valuable for manufacturers planning Australian launch strategy.
State and territory complexity: While the PBS is a national programme, state and territory health authorities manage hospital formularies, Highly Specialised Drugs programs, and public hospital procurement separately. Effective Australian market access research segments payer audiences across the national PBS system, state health authorities, and private health insurers including Medibank, Bupa, NIB, and HCF.

Australian Payer Environment and PBAC: What Market Researchers Must Know

PBAC and PBS

PBAC makes recommendations to the Australian Government on PBS listings based on clinical and cost-effectiveness evidence. PBS subsidises medicines for eligible patients following a positive PBAC recommendation. Market access research must align evidence to PBAC cost-utility methodology and the committee's clinical and economic criteria.

State Health Authorities

NSW Health, Victorian DHHS, Queensland Health, and SA Health manage state hospital formularies and Highly Specialised Drugs programs independently of the national PBS. Each state authority has distinct formulary processes and clinical advisory structures requiring dedicated payer research.

TGA and Private Payers

TGA regulatory approval precedes PBAC evaluation — the gap between approval and PBS listing creates a period requiring manufacturer-funded access programs. Australia's private health insurer market (Medibank, Bupa, NIB, HCF) covers approximately 45% of Australians and is an important secondary payer audience for pharmaceutical market researchers.

How to Evaluate a Market Research Partner for Australia

Selecting the right Australian market research partner requires criteria beyond standard RFP evaluation. Australia's PBAC evidence requirements, NHMRC compliance standards, state health authority complexity, and Asia-Pacific research extension needs demand specific capabilities.

NHMRC National Statement and Privacy Act compliance

Capability to design and execute HCP and patient research under NHMRC National Statement ethics standards and the Privacy Act 1988 (Cth), with appropriate ethics review documentation and state health records legislation compliance.

Australian AMC HCP network (Royal Melbourne, Westmead, Princess Alexandra, Peter MacCallum)

Verified access to physicians and KOLs at major Australian academic medical centres and cancer programmes across Victoria, NSW, Queensland, South Australia, and Western Australia.

PBS and PBAC payer research capability

Ability to conduct in-depth interviews with PBAC committee members, PBS formulary advisors, and state health authority decision-makers across the major Australian public payer bodies.

TGA/PBAC evidence alignment

Understanding of TGA regulatory pathways, PBAC health technology assessment methodology, and ability to design primary research evidence aligned to cost-effectiveness and PBS listing requirements.

HEOR and cost-effectiveness evidence for PBAC submissions

Capability to generate primary willingness-to-pay data, budget impact inputs, QALY-threshold intelligence, and HEOR evidence aligned to PBAC review standards and Australian health economics conventions.

Asia-Pacific multi-market research capability

Ability to extend Australian research programs to New Zealand, Singapore, South Korea, Japan, and other Asia-Pacific markets — essential for global pharmaceutical clients sequencing launches across the region.

6 Top Market Research Companies in Australia (2026)

The following profiles cover firms with demonstrated market research capability in Australia. Each is assessed by use case and market positioning.

BioNixus

Est. 2012HQ: Australia · UK (London)

Visit website

BioNixus is a specialist pharmaceutical and healthcare market research company serving Australia-based pharmaceutical, biotech, and medtech clients. Known for deep PBS payer intelligence, PBAC evidence strategy research, and verified HCP recruitment at Australian academic medical centres including Royal Melbourne Hospital, Westmead Hospital, Princess Alexandra, Royal Adelaide, and Peter MacCallum Cancer Centre.

Best for

TGA-aligned HCP surveys and KOL mapping
PBAC and PBS payer research
NHMRC-compliant market access evidence generation

IQVIA Australia

Est. 1982 (as IMS Health)HQ: Sydney, NSW, Australia

IQVIA's Australian operations provide prescription data analytics, real-world evidence, and secondary pharmaceutical intelligence for the PBS market. Primarily a data/analytics firm rather than primary research specialist.

Best for

Prescription analytics and market data
Real-world evidence and health outcomes
Secondary pharmaceutical intelligence

Ipsos Australia

Est. 1975 (Ipsos global)HQ: Sydney, NSW, Australia

Ipsos Australia is the Australian arm of the global Ipsos group, providing healthcare, consumer, and government research. Broad panel reach with generalist research capabilities across Australia.

Best for

Consumer health surveys
HCP quantitative research panels
Government and public sector research

Roy Morgan Research

Est. 1941HQ: Melbourne, VIC, Australia

Roy Morgan is Australia's longest-running market research firm, with strong consumer health, media, and social research. Primarily consumer-focused rather than pharmaceutical primary market access research.

Best for

Consumer health and wellness research
Media and social research
Pan-Australian omnibus surveys

Kantar Australia

Est. 1993 (Kantar global)HQ: Sydney, NSW, Australia

Kantar Australia provides brand tracking, consumer insights, and patient journey research. More focused on brand analytics and secondary data than primary pharmaceutical market access studies.

Best for

Brand tracking and awareness
Patient journey research
Consumer health panels

Dynata Australia

Est. 2018 (merger)HQ: Sydney, NSW, Australia

Dynata Australia specializes in online panel data collection and fieldwork across Australia and the Asia-Pacific region. Primarily a data collection provider rather than a full-service pharmaceutical MR agency.

Best for

Online panel data collection
Healthcare professional surveys
Asia-Pacific research fieldwork

KOL Mapping and Payer Research in Australia

Australian KOL mapping requires tracking influence across a geographically distributed, state-segmented landscape. Melbourne academic centres (Royal Melbourne Hospital, Peter MacCallum Cancer Centre, Alfred Hospital, Royal Children's) hold strong guideline and publication influence in oncology, haematology, cardiovascular, and transplant; Sydney institutions (Westmead Hospital, Royal Prince Alfred, St Vincent's, Children's Hospital at Westmead) combine academic prominence with large trial enrolment volumes across multiple therapy areas; Brisbane and Queensland (Princess Alexandra Hospital, Royal Brisbane and Women's) lead in tropical and infectious disease research alongside major oncology programs. Effective Australian KOL mapping segments influence by state, institution, therapy area, and prescribing volume.

Australian payer research requires access to PBAC committee members, PBS formulary advisors, and state health authority decision-makers — the most commercially important respondents in Australian pharmaceutical research. Payer interviews cover formulary listing preferences, PBAC evidence thresholds, Section 100 Highly Specialised Drugs criteria, cost-effectiveness benchmarks, and state hospital formulary dynamics. BioNixus conducts national PBS payer and private insurer interviews as dedicated payer research programs.

BioNixus conducts KOL mapping and payer research across Australia in oncology, cardiovascular, immunology, rare disease, metabolic, and other specialty areas. See our Australian pharmaceutical market research guide and top healthcare market research companies in Australia for details.

Methodology & Selection Criteria

This guide profiles firms with demonstrated market research operations in Australia as of 2026. Selection criteria: (1) active Australian operations with verified research capability, (2) relevance to healthcare, pharmaceutical, or consumer buyers in Australia, (3) established track record in Australian market research. Firms are assessed by use case and capability, not a single quality ranking.

This guide is maintained by the BioNixus research team. BioNixus is included and is transparent about its participation. For corrections or updates, contact our team.

Frequently Asked Questions

Who are the top market research companies in Australia in 2026?

Leading market research companies in Australia in 2026 include BioNixus, IQVIA Australia, Ipsos Australia, Roy Morgan Research, Kantar Australia, and Dynata Australia. BioNixus ranks first for pharmaceutical and healthcare research, with TGA-aligned primary research, verified HCP recruitment at Australian academic medical centres, and deep PBS and PBAC payer intelligence.

What is pharmaceutical market research in Australia?

Pharmaceutical market research in Australia encompasses primary and secondary research designed to support commercial, market access, and regulatory decisions in the Australian healthcare system. This includes HCP attitude-and-usage surveys, KOL mapping at academic medical centres, payer research with PBAC committee members and state health authorities, TGA and PBAC evidence-alignment studies, and health economics research. Australia's PBS system concentrates formulary decision-making in the PBAC, making PBAC-aligned evidence generation and payer research structurally different from markets with distributed multi-payer environments.

How does PBAC and PBS affect pharmaceutical market research in Australia?

The Pharmaceutical Benefits Advisory Committee (PBAC) makes recommendations to the Australian Government on listing medicines on the Pharmaceutical Benefits Scheme (PBS). PBAC assessments apply rigorous cost-effectiveness and cost-utility analysis, with a de facto QALY threshold informing listing decisions. For market researchers, PBAC creates specific research requirements: cost-effectiveness and budget impact evidence aligned to PBAC methodology, willingness-to-pay benchmarking relative to PBAC thresholds, payer perception research among PBAC committee members and state health authority advisors, and TGA regulatory timeline intelligence affecting PBS listing sequencing.

What payer research does BioNixus conduct in Australia?

BioNixus conducts payer research across Australia, including in-depth interviews with PBAC committee members and clinical advisors, PBS formulary committee research, state health authority payer interviews across NSW, VIC, QLD, SA, and WA, and private health insurer research (Medibank, Bupa, NIB, HCF). BioNixus also covers health technology assessment evidence-alignment research for products approaching PBAC submission, and conducts QALY-threshold and willingness-to-pay studies aligned to Australian HEOR standards.

How much does market research cost in Australia?

Custom market research engagements in Australia typically range from AUD $40,000 to AUD $150,000 per project depending on methodology, geography, respondent type, and research complexity. Pharmaceutical studies with NHMRC National Statement compliance requirements, specialist HCP recruitment at Australian academic medical centres, or PBAC payer depth interviews cost more than standard consumer surveys. Multi-state programs covering NSW, VIC, QLD, SA, and WA add scope versus single-state designs. Asia-Pacific extension studies incorporating New Zealand, Singapore, or other markets add further scope.

Is BioNixus NHMRC-compliant for HCP research in Australia?

Yes. BioNixus designs and executes Australian HCP research in accordance with the NHMRC National Statement on Ethical Conduct in Human Research — Australia's national research ethics framework. Studies involving HCPs at Australian academic medical centres and health systems are designed with appropriate ethics review processes, informed consent procedures, and data privacy protections under the Privacy Act 1988 (Cth) and applicable state health records legislation, including the Health Records Act (VIC) and Health Records and Information Privacy Act (NSW).

What is the PBAC cost-effectiveness threshold in Australia?

Australia does not publish a single explicit PBAC cost-effectiveness threshold, but in practice PBAC applies a QALY-based cost-utility framework informed by international HTA standards. Studies suggest an informal threshold in the range of AUD $45,000–$75,000 per QALY, though PBAC applies significant contextual judgment based on disease severity, comparator quality, and budget impact. For pharmaceutical market researchers, this creates specific research requirements: willingness-to-pay studies relative to PBAC cost-effectiveness expectations, budget impact modelling inputs, and payer perception research on QALY weighting in specific disease areas.

Can Australian market research connect to global benchmarking?

Yes. BioNixus connects Australian research to global benchmarking programs using consistent instruments and methodology across markets. Australian HCP and payer studies can be benchmarked against US, UK, EU5, Canada, and other international cohorts — essential for global pharmaceutical clients making simultaneous market access decisions across multiple countries. Australia is often included in global launch sequencing alongside the US, EU5, and Canada, and its PBAC cost-effectiveness standards are increasingly referenced in international HTA harmonisation discussions, making consistent cross-market research design a practical necessity for global pharma clients.

Related Resources

Top Healthcare Market Research Companies Australia 2026

Deep dive into the top healthcare and pharma research firms in Australia — TGA/PBAC alignment, KOL mapping, and payer research.

Pharmaceutical Market Research Australia

TGA-aligned pharmaceutical research covering HCP surveys, KOL mapping, PBAC payer research, and PBS formulary intelligence.

Healthcare Market Research Australia

Australian healthcare research overview — HCP surveys, payer research, HEOR, and patient studies.

Australia Healthcare Market Report

Market sizing, TGA and PBAC landscape, PBS outlook, and state health authority environment.

Top Market Research Companies Canada 2026

General market research firms operating across Canada for 2026.

Top Healthcare Market Research Companies Canada 2026

CADTH-aligned, TCPS 2-compliant healthcare research firms across Canada.

Plan Market Research in Australia

BioNixus delivers TGA-aligned, NHMRC-compliant pharmaceutical and healthcare market research across Australia — HCP surveys at major AMCs, KOL mapping, PBAC payer research, PBS formulary intelligence, and HEOR evidence generation. Global standards. In-market Australian execution.

Request a Proposal View Australian Research Capabilities